Haemonetics Corporation (HAE) Financials
All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | TTM | MAR 2026 | MAR 2025 | MAR 2024 | APR 2023 | APR 2022 |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenue | $1,352 | $1,334 | $1,361 | $1,309 | $1,169 | $993 |
| Cost of Revenue | $554 | $546 | $612 | $618 | $554 | $488 |
| Gross Profit | $798 | $788 | $749 | $692 | $615 | $506 |
| General & Administrative | $451 | $442 | $437 | $430 | $377 | $340 |
| Research & Development | $60 | $60 | $63 | $54 | $50 | $47 |
| Provision for Doubtful Accounts | $1 | $1 | $1 | $1 | $3 | $0 |
| Total Operating Expenses | $638 | $631 | $527 | $527 | $459 | $425 |
| Operating Income | $160 | $157 | $222 | $165 | $156 | $81 |
| Non-Operating | ||||||
| Net Interest Expense | — | -$19 | -$36 | -$20 | -$13 | -$6 |
| Other Non-Operating Income (Expense) | -$30 | -$9 | $26 | $6 | -$2 | -$11 |
| EBT (Earnings Before Tax) | $130 | $128 | $212 | $152 | $141 | $64 |
| Income Tax Expense | $34 | $31 | $44 | $34 | $26 | $20 |
| Net Income | ||||||
| Net Income | $96 | $97 | $168 | $118 | $115 | $43 |
| Per Share Data | ||||||
| Revenue Per Share | $29.58 | $28.17 | $26.82 | $25.47 | $22.73 | $19.34 |
| EPS (Basic) | $2.08 | $2.06 | $3.33 | $2.32 | $2.27 | $0.85 |
| EPS (Diluted) | $2.07 | $2.05 | $3.31 | $2.29 | $2.24 | $0.84 |
| Weighted Avg Shares (Basic) | 45.4M | 47.2M | 50.3M | 50.7M | 50.8M | 51.0M |
| Weighted Avg Shares (Diluted) | 45.7M | 47.4M | 50.7M | 51.4M | 51.4M | 51.4M |
| Shares Outstanding | 45.7M | 47.4M | 50.7M | 51.4M | 51.4M | 51.4M |
Haemonetics (HAE) financials: revenue, profit and margins
Haemonetics (HAE) generated about $1.4 billion in revenue and $96 million in net income (a 7.1% net margin) over the trailing twelve months, growing at roughly 8.9% a year. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
What is Haemonetics's (HAE) revenue?+
Haemonetics generated about $1.4 billion in revenue over the trailing twelve months. Revenue has grown at roughly 8.9% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Is Haemonetics profitable?+
Yes, Haemonetics reported about $96 million in net income over the trailing twelve months, a net profit margin of roughly 7.1%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
What are Haemonetics's profit margins?+
Haemonetics runs a gross margin of about 59.0%, an operating margin of about 11.9%, a net margin of about 7.1%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
How fast is Haemonetics growing?+
Haemonetics's revenue has compounded at roughly 8.9% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside HAE's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 31 Jul 2026, covering the period ending 27 Jun 2026, as reported to the SEC. Data last refreshed 18 Sept 2026. How this is calculated.
Fiscal year ends Apr.
Related stocks: Surgical & Medical Instruments & Apparatus
Spot a number that looks wrong?
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.